Risk of ovarian cancer with hormone therapy is associated with use of both unopposed estrogen therapy and combined estrogen-progestin therapy, whereas for endometrial cancer addition of continuous progestin decreases the estrogen induced increased risk. Less is known about risk with use of tibolone; a synthetic steroid with estrogenic, progestagenic and androgenic properties. We assessed these associations in a prospective cohort study, including all Danish women 50-79 years of age and followed 1995-2009. National Danish Registers captured individually updated exposure information, cancer cases including histology and confounding factors. Poisson regression analyses provided multiple adjusted incidence rate ratios (IRRs). More than 900,000 women were followed for 9.8 years on average; 4,513 were diagnosed with ovarian cancer and 6,202 with endometrial cancer. Compared to women never on postmenopausal hormone therapy, current users of tibolone had an increased IRR for ovarian cancer (1.42(95% confidence interval [CI], 1.01-2.00) and serous ovarian tumors (2.21(95%CI 1.48-3.32)). The risk increased with duration of use, particularly for serous ovarian tumors. Compared to never users, the IRR of endometrial cancer was 3.56(95%CI 2.94-4.32) among current users of tibolone and 3.80(95%CI 3.08-4.69) of Type I endometrial cancer. The steepest risk increase with duration of use was for Type I tumors. In conclusion, tibolone is associated with increased risk for ovarian and endometrial cancer overall; and particular the risk of serous ovarian tumors and Type I endometrial cancer. Because the associations are stronger with increasing durations of use -and for hormone sensitive tumors -the results seem indicative of causality.
Introduction
Risk of ovarian cancer with hormone therapy (HT) has been established to be associated with exposure to both unopposed estrogen therapy and combined estrogen progestin therapy. 1 The risk seems based on an increased risk of serous and endometrioid tumors whereas no increased risk of mucinous and clear-cell tumors were found. The diverse influence of hormones on tumor types supports the suggestion that different ovarian tumors should be viewed as having different etiologies. 2 The risk of endometrial cancer is increased with use of unopposed estrogen and sequential combined therapy whereas continuous combined therapy seems risk free. 3 Generally stronger associations are found between hormone use and risk of Type I endometrial tumors which are considered the most hormone sensitive endometrial tumors. 4 Type I endometrial tumors of endometrioid histology are developed from abnormal proliferations (i.e., endometrial hyperplasia) driven by hormonal mechanisms. Type II endometrial tumors arise often from atrophic endometrium in a less hormone-dependent manner. 4 Apart from conventional HT with estrogen and progestin, tibolone is prescribed to menopausal women in several European countries. Tibolone is a synthetic steroid with estrogenic, progestagenic and androgenic properties. Tibolone has metabolites that act as both agonists and antagonists of the progesterone and androgen receptors. 5 The risk of gynecological cancer associated with tibolone has been investigated by few. [6] [7] [8] [9] [10] [11] Prior studies did not assess the risk of specific types of ovarian tumors, thus the influence of tibolone on the hormone sensitive ovarian tumors is unknown. Regarding endometrial cancer we have documented an increased risk for endometrial cancer of 3.56 (95%CI 2.94-4.32) among women on tibolone; a risk that was stronger for Type I endometrial tumors. However, data on the influence of duration of tibolone use on risk of Type I endometrial tumors has not been published; and our previous study with 11 years follow-up had too few ovarian cancers exposed to tibolone to determine risk estimates. 2, 11 On this background we aimed to analyze the risk of ovarian and endometrial tumors associated with use of tibolone and duration of use in a national setting with 15 years follow-up.
Materials and Methods
The Danish Sex Hormone Register Study is a nationwide cohort of Danish women merging information from nationwide Danish registers using participants' personal identification numbers as the key identifiers: (1) the National Register of Medicinal Product Statistics (National Prescription Register) (2) the Danish Cancer Registry (3) the Pathology Register (4) the Danish National Patient Register and (5) Statistics Denmark. The study has been described in previous publications. 11, 12 Our study population includes women aged 50-79 years sometime between January 1, 1995 and December 31, 2009. We excluded women who had any type of cancer except non-melanoma skin cancer (ICD10 C44) and for ovarian cancer analyses women who had bilateral oophorectomy or bilateral salpingo-oophorectomy before entry. Correspondingly for endometrial cancer analyses women who had a hysterectomy before entry were excluded.
From the National Register of Medicinal Product Statistics the exposure information on redeemed HT prescriptions was updated daily for all individuals during follow-up. The register includes information on the date of the redeemed prescriptions and the specific Anatomical Therapeutic Chemical code, dose, number of packages, defined daily doses and route of administration (tablet, patch, gel, etc.) Based on this a daily assessment of exposure status and information on switch in the type of hormone used was calculated. The specific Anatomical Therapeutic Chemical codes included in our study have been described previously. 13 Hormone use was categorized according to "never postmenopausal hormone therapy (HT), current use of tibolone, current use of other HT, previous systemic HT and current/previous local hormones." Women were at every given time during followup allocated to the product taken longest at that given time. Duration of use was categorized as < 2, 2-4, 5-9, 101 years. The Danish Cancer Registry was used to identify primary invasive ovarian and endometrial cancers using the "International Classification of Diseases for Oncology" topography code 183.0 and C54.0-C55.9, respectively and morphology codes ending with "3. 
Analysis
The data were analyzed with Poisson regression analysis using SAS statistical software, version 9.1 (SAS Institute, Inc., Cary, NC). Incidence rate ratios and 95% confidence intervals were calculated for each model. Age was calculated using birth dates, which were extracted from personal identification numbers. Age was used as timescale in the Poisson regression analyses and data were divided into 5-year age bands (50-54 years, etc.). As the National Register of Medicinal Product Statistics is considered complete from 1, January 1995, this was the start of follow-up of women aged 50 years or older, while women who turned 50 years of age sometime during follow-up were followed from their 50th birthdays.
The analyses were performed by following the entire study population of peri-or post-menopausal women from study entry until event or end of follow-up 31, December 2009. Follow-up time was censored at time of death, emigration, event of other cancers than the outcomes (except nonmelanoma skin cancer) and at 80 years of age. In the analyses assessing risk for ovarian cancer follow-up time was also censored at time of bilateral oophorectomy or salpingooophorectomy. In the analyses assessing risk for endometrial cancer, follow-up time was censored at time of hysterectomy. Separate analyses were conducted to assess the tibolone associated risk of cancer by different types of cancers.
All tests were two-sided with a 5% significance level. The National Register of Patients and Statistics Denmark provided information on potential confounders. Potential confounders were number of births, sterilization, unilateral oophorectomy or salpingo-oophorectomy, endometriosis, infertility and educational status in 1995. Furthermore, we adjusted for the year in which tibolone was prescribed to account for possible differences in hormone prescription during follow-up. The following variables were time-dependent, and data were updated daily: HT variables (including tibolone), sterilization, unilateral oophorectomy or salpingooophorectomy, number of births, hypertension and diabetes. Women who had been diagnosed with endometriosis or infertility were considered to have that condition throughout What's new? The synthetic steroid tibolone is widely used in Europe as a form of hormone replacement therapy for menopausal women, owing to its estrogenic, progestagenic and androgenic properties. However, whether tibolone use is associated with an increased risk of ovarian cancer, similar to traditional hormone therapies, is unknown. Here, analyses of data from nationwide registries in Denmark suggest that tibolone increases overall risk of ovarian and endometrial cancer. Its use was associated in particular with elevated risk of hormone-sensitive histological cancer types, namely serous ovarian tumors and Type I endometrial tumors. Risk increased with longer duration of tibolone use.
the study period. The crude models included exposure, age and year of study. Sensitivity analyses were conducted by restricting the analysis to women exposed to only one type of hormone therapy during follow-up; which was done by censoring women at time of switch to another type of HT.
The reference group was women who had never used any hormones.
Results
From 1995 to 2009, a total of 988,524 peri-or postmenopausal women with no previous cancer (except nonmelanoma skin cancer) or bilateral oophorectomy accumulated 9.0 million person-years; corresponding to an average follow-up of 9.8 years. A total of 914,595 had no previous cancer or hysterectomy. The number of incident malignant ovarian cancers during the study period was 4,513. Of these, 2,221 were serous ovarian cancer 454 endometrioid, 388 mucinous and 206 clear cell tumors. The number of endometrial cancers was 6,202 of which 4,972 were Type I endometrial cancers and 500 Type II tumors.
At the end of follow-up 64% of the women had not been taking HT, 17% were previous users of systemic hormones, 0.4% were current users of tibolone, 8% were current users of systemic hormones other than tibolone and 11% were ever users of local hormones.
Characteristics of the study population are shown in Table 1 .
Tibolone and ovarian cancer
Current users of tibolone had an overall increased incidence rate ratio (IRR) of ovarian cancer of 1.42 (95%CI 1.01-2.00) compared to women who had never used HT. When restricting the analyses to serous ovarian tumors the IRR was 2.21 (95%CI 1.48-3.32), compared to never users (Table 2) . Among women exposed to tibolone the number of endometrioid, mucinous or clear cell ovarian tumors were too few to determine risk estimates.
Increasing durations of tibolone were positively associated with both risk of epithelial ovarian cancer overall and of serous ovarian tumors ( (Table 2) , compared to never users.
Tibolone and endometrial cancer
The IRR of endometrial cancer among current users of tibolone was 3.56 (95%CI 2.94-4.32) and of Type I endometrial tumors 3.80 (95%CI 3.08-4.69), compared to never users. The risk was increased at any duration and increased with increasing duration (Table 3 ). Compared to never use, longterm use (101 years) showed an increased IRR of 3.80 (95%CI 2.56-5.64) for endometrial cancer overall and 4.70 (95%CI 3.13-7.04) of Type I tumors.
The risk estimates for endometrial cancer among current users of other types of HT, was 2.10 (95%CI 1.96-2.25), and 2.23 (95%CI 2.07-2.40) for Type I tumors, compared to never users. The risk among previous users of systemic HT was 1.38 (95%CI 1.28-1.49) for endometrial cancer and 1.55 (95%CI 1.42-1.69) of Type I tumors (Table 3 ), compared to never users.
Crude and adjusted incidence rate ratios were approximately similar.
Discussion
In this national prospective cohort study we found postmenopausal hormone substitution with tibolone was associated with an increased risk of gynecological hormone sensitive cancers. The most pronounced increased risk was found for among the histological subtypes considered the most hormone sensitive tumors. The use of tibolone in Denmark resembles the pattern of use in other European countries. In an European prospective investigation 3% of current users used tibolone the corresponding percentage in this national cohort study was 4.8%, whereas in the English Million Women Study 9% reported tibolone as the hormone replacement therapy last used at recruitment. 7 We found women using tibolone had an IRR of ovarian cancer of 1.42(95%CI 1.01-2.00) and of 2.21(95%CI 1.48-3.32) for serous ovarian tumors, compared to never users. The risk increased with duration most explicit for presumed more hormone sensitive serous ovarian tumors. 4 No other studies investigated the association between tibolone and serous ovarian tumors. The Million Women Study that included a large cohort of women screened for breast cancer analyzed the risk of ovarian cancer overall with use of tibolone which 22,344 did. They did not find an association as the relative risk was 1.07(95%CI 0.81-1.41), compared to never use, however the estimate was not significantly different from other types of hormone replacement therapy where a significant increased risk of 1.23(1,09-1.38) was found. 8 A recent Finnish case-control study based on national registries included all ovarian cancer cases (n 5 3,958) during 1995-2007 of which 1.5% were exposed to tibolone. They found no higher risk of ovarian cancer; as the risk with <1 year and >1 year use of tibolone was 0.86(95%CI 0.58-1.29) and 1.01(95%CI 0.64-1.60), respectively. 9 In accordance with our findings, an European prospective Investigation of 370,000 women after which after exclusion constituted 126,290 postmenopausal healthy women with relevant information found that tibolone was associated with greater hazard ratio of ovarian cancer of 2.19(1.06-4.50). We have previously documented that tibolone use is associated with an increased risk of endometrial cancer, and particularly Type I endometrial tumors. This finding is in accordance with findings from the Million Women Study that suggests a greater risk of 79% among women using tibolone, however our estimates are three times higher. 7 We now additionally document an increasing risk with increasing duration of tibolone, that was steepest for Type I tumors. The RR with long-term use was 4.70 (95%CI 3.13-7.04).
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Strength and Weaknesses
Our nationwide study is the largest cohort study of >900,000 women followed for 8.9 years in average. The follow-up until diagnosis of cancer, emigration, death or end of study was complete and our large number of cancers permitted us to perform sub-analyses of specific hormone sensitive tumors. The validity of our outcomes is considered to be high, because the Danish Cancer Register has both a high level of completeness and validation of their diagnoses in the National pathology database. [14] [15] [16] The validity of the information on exposure to tibolone is also presumed to be high because recall bias was eliminated, since the information on the prescribed and redeemed tibolone was transferred electronically from the pharmacies by barcodes. The pharmacy records also provided daily assessment of exposure status and information on switch in the type of hormone used. Thus our exposure variable was timedependent and updated daily. Information on tibolone use and cancers was registered without the aim of exploring the association between tibolone and the clinical outcomes, making a differential ascertainment of exposure or cancer incidence unlikely. We excluded women with previous cancer because this might affect both use of tibolone and the subsequent risk of cancer. Our results were adjusted for possible confounders such as age, year in which the hormones were prescribed, educational, status, hypertension, diabetes and number, of births. We accounted for women taking less than the defined daily dose by prolonging exposed periods "current hormone use" by 4 months. 11, 12 Finally, our sensitivity analyses showed that our results remained stable after restricting the analysis to women exposed to only one type of hormone therapy during follow-up. Because the information on tibolone use is measured as redeemed prescriptions we do not know if the product is actually taken. However, it seems unlikely that women continue to redeem and pay for prescriptions that they do not use. Thus, this potential misclassification of true "non-users" as "current users" is most likely to be present only for the first redeemed prescription; and while this prescription is valid i.e. these women are falsely assumed users until the supply of that prescription runs out, where after the women are allocated to the group of previous users. Therefore, if any bias this would affect a very small amount of the total "current user time" in the study; and could therefore have caused a minor underestimation of the associations assessed.
We were not able to adjust for body mass index, physical activity, smoking or oral contraceptive use. If tibolone users are leaner, more physically active, less often smokers, more often users of oral contraceptives and fewer have a family disposition for cancer this could have underestimated the increased risk of ovarian and endometrial cancers. However, it seems unlikely that these factors are correlated with duration of tibolone use i.e. that increasing duration of tibolone use should be associated with amount of physical activity. Thus, (except for oral contraceptive use) these potential confounders are unlikely to have any influence on the increasing risk of ovarian and endometrial cancers found with increasing durations of tibolone use. However, because women on postmenopausal hormone therapy seem more often to have used oral contraceptives 7,9 -and long-term hormone users might also be long-term oral contraceptive users -this might have caused an underestimation of the associations assessed; since oral contraceptive use is associated with a decreased risk of both ovarian and endometrial cancer. In conclusion, the associations found in our study might be underestimated by a beneficial influence of oral contraceptive use among the hormone users. However, any potential different distribution of characteristic among users and non-users of tibolone -including use of oral contraceptivescannot explain the diverse influence of tibolone on tumor types. The stronger associations with hormone sensitive tumors point toward a causal association.
In conclusion, tibolone is associated with an increased risk for ovarian and endometrial cancer overall; and increases with increasing durations of use. Particularly the stronger associations found with risk of the histological tumor types considered most hormone sensitive (i.e., serous ovarian tumors and Type I endometrial tumors) seems indicative of a causal relationship.
